en · de · es · fr · pt
dihexa-notes.peptides6908.com › Guide › Dihexa Chemical Identity And Origin — Quick Reference

Dihexa Chemical Identity And Origin — Quick Reference

By Editorial Desk · published 2025-07-08 · last reviewed 2025-08-09 · Guide

The short version of HGF/c-Met fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-08-09 and is reviewed periodically as new material appears.

Dihexa Chemical Identity and Origin

Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.

The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.

Chemical Identity and Research Background

Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.

Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.

The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.

Dihexa at a glance

PropertyValueNotes
Common nameDihexaShorthand used in research literature and supplier catalogs.
CAS Registry Number1401708-83-5Identifier assigned to the synthetic peptide.
Molecular formulaC27H44N4O5Reported formula; verify with a certificate of analysis.
AppearanceWhite to off-white powderTypical form for lyophilized research peptides.
Typical storage−20 °C or below, desiccatedCommon condition for peptide stability.

Preclinical Research and Regulation

Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.

Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.

Related pages on this site

Mechanism And Laboratory Characterization

The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.

Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.

Mechanism and Research Status

The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.

Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.

Proposed Mechanism and Laboratory Handling

Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.

Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.

Supporting material

Emily Maitlis, TV newscaster and reporter Winston Marshall (born 20 December 1987); journalist and podcaster; former Mumford & Sons musician; has written for Jewish Chronicle (on BDS), Daily Mail, Newsweek, Die Welt, Dissident Muse Journal, RealClear Politics, The Spectator, David Horowitz' Frontpage Magazine, Hot Press, Common Sense with Bari Weiss; has interviewed Eylon Levy, Natan Sharansky, Douglas Murray, mostly focusing on the Israel-Hamas conflict. Monty Meth (3 March 1926 – 14 March 2021) was a British journalist who was editor of the Daily Mail; was member of the Young Communist League;appointed Member of the Order of the British Empire (MBE) in the 2007 Queen's Birthday Honours for services to the communities of Enfield and Bethnal Green.; author of Here to Stay: A Study of Good Practices in the Employment of Coloured Workers 1972; Brothers to all Men? A Report on Trade Union Actions and Attitudes on Race Relations.

=== COVID-19-related marketing and government agency responses === Although according to the NIH no stem cell treatments have been approved for COVID-19, and the agency recommends against the use of MSCs for the disease, some stem cell clinics began marketing both unproven and non-FDA-approved stem cells and exosomes for COVID-19 in 2020. The FDA took prompt action by sending letters to the firms in question. The FTC also warned a stem cell firm for misleading COVID-19-related marketing.

Promoting the rapid exchange of information during food safety events; Sharing information on important food safety issues of global interest; Promoting partnership and collaboration between countries; and Helping countries strengthen their capacity to manage food safety risks. Membership to INFOSAN is voluntary, but is restricted to representatives from national and regional government authorities and requires an official letter of designation. INFOSAN seeks to reflect the multidisciplinary nature of food safety and promote intersectoral collaboration by requesting the designation of Focal Points in each of the respective national authorities with a stake in food safety, and a single Emergency Contact Point in the national authority with the responsibility for coordinating national food safety emergencies; countries choosing to be members of INFOSAN are committed to sharing information between their respective food safety authorities and other INFOSAN members. The operational definition of a food safety authority includes those authorities involved in: food policy; risk assessment; food control and management; food inspection services; foodborne disease surveillance and response; laboratory services for monitoring and surveillance of foods and foodborne diseases; and food safety information, education and communication across the farm-to-table continuum.

Sources: en.wikipedia.org

Notes from published material

Human activities have affected stocks of many species of teleost, through overfishing, pollution and global warming. Among many recorded instances, overfishing caused the complete collapse of the Atlantic cod population off Newfoundland in 1992, leading to Canada's indefinite closure of the fishery. Pollution, especially in rivers and along coasts, has harmed teleosts as sewage, pesticides and herbicides have entered the water. Many pollutants, such as heavy metals, organochlorines, and carbamates interfere with teleost reproduction, often by disrupting their endocrine systems. In the roach, river pollution has caused the intersex condition, in which an individual's gonads contain both cells that can make male gametes (such as spermatogonia) and cells that can make female gametes (such as oogonia). Since endocrine disruption also affects humans, teleosts are used to indicate the presence of such chemicals in water. Water pollution caused local extinction of teleost populations in many northern European lakes in the second half of the twentieth century. The effects of climate change on teleosts could be powerful but are complex. For example, increased winter precipitation (rain and snow) could harm populations of freshwater fish in Norway, whereas warmer summers could increase growth of adult fish. In the oceans, teleosts may be able to cope with warming, as it is simply an extension of natural variation in climate. It is uncertain how ocean acidification, caused by rising carbon dioxide levels, might affect teleosts.

==== On-farm efficiency ==== On-farm, precision agriculture technologies can minimize inputs required for a given yield. For example, variable-rate application (VRA) technologies can apply precise amounts of water, fertilizer, pesticide, herbicide, etc. A number of empirical studies find that VRA improves input use efficiency. Using VRA alongside geo-spatial mapping, farmers can apply inputs to hyper-localized regions of their farm, sometimes down to the individual plant level. Reducing input use lowers costs and lessens negative environmental impacts. Furthermore, empirical evidence indicates precision agriculture technologies can increase yields. On U.S. peanut farms, guidance systems are associated with a 9% increase in yield, and soil maps are associated with a 13% increase in yield. One study in Argentina found that a precision agriculture approach based on crop physiological principles could result in 54% higher farm output. Digital agriculture can improve the allocative efficiency of physical capital within and between farms. Often touted as "Uber for tractors," equipment-sharing platforms like Hello Tractor, WeFarmUp, MachineryLink Solutions, TroTro Tractor, and Tringo facilitate farmer rental of expensive machinery, an on-demand model with parallels to Public transport. These platforms are an example of agricultural Fleet management, often coordinated with Fleet management software. By facilitating a market for equipment sharing, telematics technology ensures fewer tractors sit idle and allows owners to make extra income.

Research has implicated UPS defects in the pathogenesis of neurodegenerative and myodegenerative disorders, including Alzheimer's disease, Parkinson's disease and Pick's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, Creutzfeldt–Jakob disease, and motor neuron diseases, polyglutamine (PolyQ) diseases, muscular dystrophies and several rare forms of neurodegenerative diseases associated with dementia. As part of the ubiquitin–proteasome system (UPS), the proteasome maintains cardiac protein homeostasis and thus plays a significant role in cardiac ischemic injury, ventricular hypertrophy and heart failure. Additionally, evidence is accumulating that the UPS plays an essential role in malignant transformation. UPS proteolysis plays a major role in responses of cancer cells to stimulatory signals that are critical for the development of cancer. Accordingly, gene expression by degradation of transcription factors, such as p53, c-jun, c-Fos, NF-κB, c-Myc, HIF-1α, MATα2, STAT3, sterol-regulated element-binding proteins and androgen receptors are all controlled by the UPS and thus involved in the development of various malignancies. Moreover, the UPS regulates the degradation of tumor suppressor gene products such as adenomatous polyposis coli (APC) in colorectal cancer, retinoblastoma (Rb). and von Hippel–Lindau tumor suppressor (VHL), as well as a number of proto-oncogenes (Raf, Myc, Myb, Rel, Src, Mos, ABL). The UPS is also involved in the regulation of inflammatory responses.

Sources: en.wikipedia.org

Background from the literature

Recently VESA has experienced quite a few complaints regarding troublesome DisplayPort operation that ended up being caused by improperly made DisplayPort cables. These "bad" DisplayPort cables are generally limited to non-DisplayPort certified cables, or off-brand cables. To further investigate this trend in the DisplayPort cable market, VESA purchased a number of non-certified, off-brand cables and found that an alarmingly high number of these were configured improperly and would likely not support all system configurations. None of these cables would have passed the DisplayPort certification test, moreover some of these cables could potentially damage a PC, laptop, or monitor.

Leconotide (INN; development codes CNSB004 and AM336; also known as ω-conotoxin CVID) is an ω-conotoxin peptide isolated from the venom of Conus catus which is under investigation as an analgesic drug for the treatment of pain conditions. It acts as an N-type voltage-gated calcium channel (Cav2.2) blocker and is highly selective for this channel over the related P/Q-type voltage-gated calcium channel (Cav2.1). Relative to ziconotide, leconotide is advantageous in that it is significantly less toxic, and for that reason can be administered intravenously as opposed to via intrathecal injection.

== Chemistry == The substance is a white crystalline powder. It is freely soluble in methanol and acetone; soluble in water, ethanol, 0.01 M hydrochloric acid, and 0.01 M sodium hydroxide; sparingly soluble in isopropyl alcohol and acetonitrile; slightly soluble in diethyl ether; and very slightly soluble in isopropyl ether.

Sources: en.wikipedia.org

Frequently asked questions

What is dihexa?

Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.

Where does dihexa come from?

It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.

Is dihexa the same as angiotensin IV?

No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.

What is dihexa?

Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.

Network